The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Mon., Jul. 6, 1:48 PM

Slide #7. bluebird bio, Inc. Secondary Offering

Company: bluebird bio, Inc. (NASDAQ:BLUE)
Date announced: 6/23/2015
Shares Offered: 2,941,176
Date of Pricing: 6/23/2015
Price Per Share: $170.00
Secondary Offering Details: bluebird bio, Inc. (NASDAQ:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies, today announced that it has commenced an underwritten public offering of $400 million of its common stock. bluebird bio also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. - updated 6/24 - bluebird bio, Inc. (NASDAQ:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies, today announced the pricing of an underwritten public offering of 2,941,176 shares of its common stock at a public offering price of $170.00 per share, before underwriting discounts. In addition, bluebird bio has granted the underwriters a 30-day option to purchase from it up to an additional 441,176 shares of common stock.

bluebird bio is a clinical-stage biotechnology company focused on genetic and orphan diseases using gene therapy products. Co.'s primary product candidate is called Lenti-D, which Co. it is developing to treat patients with adrenoleukodystrophy. Co.'s other product candidate is called LentiGlobin, which it is developing to treat patients with ?-thalassemia and sickle cell disease. Co also has collaborated with Celgene Corporation to discover, develop and commercialize disease-altering gene therapies in oncology. The collaboration focuses on applying gene therapy technology to genetically modify a patient's own T cells to target and destroy cancer cells.
Open the BLUE Page at The Online Investor »

Company Name:  bluebird bio Inc
Website:  www.bluebirdbio.com
Sector:  Biotechnology
Number of ETFs Holding BLUE:  13
Total Market Value Held by ETFs:  $138.43M
Total Market Capitalization:  $5.36B
% of Market Cap. Held by ETFs:  2.58%
 

Open the BLUE Page at The Online Investor (in a new window) »

July 6, 2015    1:48 PM Eastern
Quotes delayed 20 minutes



Strong Buy (4.00 out of 4)
86th percentile
(ranked higher than approx. 86% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2015, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.